At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
MK-3475drug
Likely dose
MK-3475 1mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers
In Brief
A Phase 2 clinical trial evaluating MK-3475 for Metastatic Breast Cancer. Completed, enrolled 58 participants across 11 sites in 5 countries.
Detailed Summary
Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2- positive metastatic breast cancers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesAustralia, Austria, Belgium, France, Italy
CollaboratorsBreast International Group
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartDec 2014
Primary CompletionAug 2017
TodayJul 2026
First PostedMay 2, 2014
Enrollment StartDec 1, 2014
Primary CompletionAug 4, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.2 years ago
Interventions
MK-3475drug
The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.